Abstract
Lipoxygenases (LOXs), cytochromes P450 (CYPs) and cyclooxygenases (COXs) catalyze peroxidation of unsaturated fatty acids. In humans they convert arachidonic acid into a variety of eicosanoids, which play a role in all inflammatory responses, cardiovascular and kidney diseases, Alzheimers, cancer and other ailments. Blocking one pathway can prompt the body to switch to the available alternatives. In contrast to CYP and COX, LOX has a non-heme iron co-factor. Several LOXs are produced or stress-induced in the human body. They share the same mechanism, but differ in sequence causing catalysis on the same substrate to be regio- and stereospecific. The action of 15-LOXs could be pro- or anti-inflammatory, and pro- or anticarcinogenic. Depending on the dose, LOXs inhibitors can induce or inhibit other oxygenases. Inhibition of these enzymes presents a great challenge in solving the problem of how to control their action and treat diseases, without causing severe side effects and maintaining/restoring a delicate equilibrium between them. Research on CYPs and COXs is more advanced, while studies of LOXs are lagging behind. This article presents a brief review about LOX structures and inhibition, their involvement in human diseases, and their interplay with other oxidoreductases.
Keywords: Lipoxygenase, fatty acids, inhibition, structure, NSAIDs, regulation of oxygenases, eicosanoids in human diseases
Current Enzyme Inhibition
Title: Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development
Volume: 3 Issue: 2
Author(s): Ewa Skrzypczak-Jankun, Joanna Chorostowska-Wynimko, Steven H. Selman and Jerzy Jankun
Affiliation:
Keywords: Lipoxygenase, fatty acids, inhibition, structure, NSAIDs, regulation of oxygenases, eicosanoids in human diseases
Abstract: Lipoxygenases (LOXs), cytochromes P450 (CYPs) and cyclooxygenases (COXs) catalyze peroxidation of unsaturated fatty acids. In humans they convert arachidonic acid into a variety of eicosanoids, which play a role in all inflammatory responses, cardiovascular and kidney diseases, Alzheimers, cancer and other ailments. Blocking one pathway can prompt the body to switch to the available alternatives. In contrast to CYP and COX, LOX has a non-heme iron co-factor. Several LOXs are produced or stress-induced in the human body. They share the same mechanism, but differ in sequence causing catalysis on the same substrate to be regio- and stereospecific. The action of 15-LOXs could be pro- or anti-inflammatory, and pro- or anticarcinogenic. Depending on the dose, LOXs inhibitors can induce or inhibit other oxygenases. Inhibition of these enzymes presents a great challenge in solving the problem of how to control their action and treat diseases, without causing severe side effects and maintaining/restoring a delicate equilibrium between them. Research on CYPs and COXs is more advanced, while studies of LOXs are lagging behind. This article presents a brief review about LOX structures and inhibition, their involvement in human diseases, and their interplay with other oxidoreductases.
Export Options
About this article
Cite this article as:
Skrzypczak-Jankun Ewa, Chorostowska-Wynimko Joanna, Selman H. Steven and Jankun Jerzy, Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development, Current Enzyme Inhibition 2007; 3 (2) . https://dx.doi.org/10.2174/157340807780598350
DOI https://dx.doi.org/10.2174/157340807780598350 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Current Neuropharmacology New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease
Recent Patents on Cardiovascular Drug Discovery Opinion: [Withdrawal of Rimonabant – Walking the Tightrope of 21st Century Pharmaceutical Regulation?]
Current Drug Safety The Chemistry and Pharmacology of Tetrahydropyridines
Current Medicinal Chemistry Pharmacogenetic Studies of Psychotropic Drug-Induced Adverse Effects
Current Pharmacogenomics MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Monocytes Mediate HIV Neuropathogenesis: Mechanisms that Contribute to HIV Associated Neurocognitive Disorders
Current HIV Research Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
Current Pharmaceutical Design An Efficient and Eco-Friendly Procedure for the Synthesis of Hantzsch Ethyl 1,4-Dihydro-2,6-Dimethylpyridine-3,5-Dicarboxylates Under Mild and Green Conditions
Letters in Organic Chemistry Computational Study of Nanosized Drug Delivery from Cyclodextrins, Crown Ethers and Hyaluronan in Pharmaceutical Formulations
Current Topics in Medicinal Chemistry Anti-Aging Property of G2013 Molecule as a Novel Immunosuppressive Agent on Enzymatic and Non-Enzymatic Oxidative Stress Determinants in Rat Model
Current Drug Discovery Technologies Current Burden of Hepatitis C Virus Infection Among Injecting Drug Users: A Mini Systematic Review of Prevalence Studies
Infectious Disorders - Drug Targets The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Atomoxetine Protects Against NMDA Receptor-mediated Hippocampal Neuronal Death Following Transient Global Cerebral Ischemia
Current Neurovascular Research Key Sites for P2X Receptor Function and Multimerization: Overview of Mutagenesis Studies on a Structural Basis
Current Medicinal Chemistry Editorial (Hot Topic: New Advances of Drug Design in Alzheimer's Disease)
Current Bioactive Compounds Intravenous Magnesium – Lidocaine - Ketorolac Cocktail for Postoperative Opioid Resistant Pain: A Case Series of Novel Rescue Therapy
Reviews on Recent Clinical Trials